Three compounds dominate the GLP-1 receptor agonist landscape: semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and retatrutide (currently in Phase 3 clinical trials). They share a common mechanism — activating the GLP-1 receptor to reduce appetite and regulate blood glucose — but they differ meaningfully in how many receptors they target, how much weight loss the clinical data shows, and where they sit in terms of regulatory approval and availability.
This comparison breaks down the clinical evidence, pharmacokinetic profiles, and practical differences between all three. The data presented comes from published clinical trials. Individual responses vary significantly — population averages from controlled trials do not predict any single person's outcome.
The GLP-1 Landscape
GLP-1 (glucagon-like peptide-1) is a naturally occurring incretin hormone released by the gut after eating. It does several things simultaneously: it signals the pancreas to release insulin, it slows gastric emptying (food stays in the stomach longer, promoting satiety), and it acts on appetite centers in the brain to reduce hunger. Natural GLP-1 has a half-life of about 2 minutes — it is rapidly degraded by the DPP-4 enzyme. The pharmaceutical versions are engineered to resist this degradation, extending their half-life to days rather than minutes.
What differentiates the three compounds is how many incretin receptors they target:
- Semaglutide targets the GLP-1 receptor only — a single-agonist approach. It was the first in this generation to demonstrate dramatic weight loss in clinical trials and remains the most widely prescribed.
- Tirzepatide targets both the GLP-1 and GIP receptors — a dual-agonist approach. GIP (glucose-dependent insulinotropic polypeptide) is another incretin hormone that enhances insulin secretion and appears to contribute additional metabolic benefits beyond GLP-1 activation alone.
- Retatrutide targets GLP-1, GIP, and glucagon receptors — a triple-agonist approach. The glucagon receptor activation adds a thermogenic and lipolytic component: glucagon mobilizes stored glycogen and fatty acids, potentially increasing energy expenditure in addition to reducing intake.
The pattern is clear: each successive compound activates more receptors, and the clinical data suggests incrementally greater efficacy with each additional receptor target. Whether this pattern holds in Phase 3 data for retatrutide remains to be confirmed.
Mechanism Comparison
| Compound | Receptors | Type | Primary Mechanisms |
|---|---|---|---|
| Semaglutide | GLP-1 | Single agonist | Appetite suppression, delayed gastric emptying, enhanced insulin secretion, reduced glucagon secretion |
| Tirzepatide | GLP-1 + GIP | Dual agonist | All GLP-1 effects plus GIP-mediated enhanced insulin sensitivity, improved lipid metabolism, potentially reduced GI side effects vs GLP-1 alone |
| Retatrutide | GLP-1 + GIP + Glucagon | Triple agonist | All dual-agonist effects plus glucagon-mediated increased energy expenditure, hepatic fat mobilization, thermogenesis |
The GIP receptor component in tirzepatide and retatrutide is pharmacologically interesting. GIP was historically considered an "obesity hormone" because it promotes fat storage in the fed state. However, at the pharmacological doses used in these drugs, GIP receptor activation paradoxically appears to enhance the weight loss effects of GLP-1 rather than opposing them. The mechanism is not fully understood — it may involve desensitization of the GIP receptor at high doses, or synergistic effects on central appetite circuits that differ from the peripheral metabolic effects.
Retatrutide's glucagon receptor activation adds a fundamentally different dimension. While GLP-1 and GIP primarily reduce energy intake (you eat less), glucagon increases energy expenditure (you burn more). Glucagon stimulates hepatic gluconeogenesis, glycogenolysis, and lipolysis — mobilizing stored energy. In the context of adequate caloric intake, this would be counterproductive. In the context of GLP-1-driven appetite suppression creating a caloric deficit, the glucagon component may amplify fat loss beyond what appetite reduction alone achieves.
Weight Loss Data
The clinical trial data for these three compounds comes from large, randomized, placebo-controlled studies. The numbers below represent population averages — individual results within these trials ranged from minimal weight loss to over 30% in some participants.
| Compound | Trial | Duration | Max Dose | Avg Weight Loss |
|---|---|---|---|---|
| Semaglutide | STEP 1 | 68 weeks | 2.4 mg/week | ~14.9% |
| Semaglutide | STEP 3 | 68 weeks | 2.4 mg/week | ~16.0% |
| Tirzepatide | SURMOUNT-1 | 72 weeks | 15 mg/week | ~22.5% |
| Tirzepatide | SURMOUNT-2 | 72 weeks | 15 mg/week | ~14.7% |
| Retatrutide | Phase 2 | 48 weeks | 12 mg/week | ~24.2% |
These numbers are not directly comparable across trials. Different trial populations, durations, inclusion criteria, and baseline BMIs all influence outcomes. SURMOUNT-2, for example, enrolled participants with type 2 diabetes (who typically lose less weight on GLP-1 agonists than non-diabetic participants), which partly explains its lower number vs SURMOUNT-1. The retatrutide data comes from Phase 2 only (smaller sample size, potentially more optimistic than Phase 3 will show). The trend across receptor targets is consistent, but the exact magnitude of difference will only be clear when Phase 3 retatrutide data and head-to-head studies are available.
A notable data point within the SURMOUNT-1 trial: approximately 36% of participants in the 15 mg tirzepatide group achieved 25% or greater body weight reduction, and roughly 63% achieved 20% or greater. In the retatrutide Phase 2 trial, over 25% of participants in the highest dose group lost more than 30% of their body weight. These are population-level results that were historically unprecedented for any pharmacological weight loss intervention.
Weight regain after discontinuation has been observed across all three compounds. The STEP 1 extension trial showed that participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year. Similar patterns have been observed with tirzepatide. This suggests that for sustained weight management, ongoing use may be necessary — these compounds address the physiology of appetite regulation for as long as they are active in the system, but do not permanently reset the body's weight set point.
Dosing and Titration
All three compounds are administered as weekly subcutaneous injections. Each follows a titration schedule — starting at a low dose and gradually increasing over weeks to months. Titration serves two purposes: it allows the GI system to adapt (reducing nausea and other side effects), and it allows the prescriber to find the lowest effective dose for each individual.
| Compound | Starting Dose | Titration Steps | Max Dose | Time to Max |
|---|---|---|---|---|
| Semaglutide | 0.25 mg | 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg | 2.4 mg/week | ~16-20 weeks |
| Tirzepatide | 2.5 mg | 2.5 → 5.0 → 7.5 → 10 → 12.5 → 15 mg | 15 mg/week | ~20-24 weeks |
| Retatrutide | 0.5 mg | 0.5 → 1.0 → 2.0 → 4.0 → 8.0 → 12.0 mg | 12 mg/week | ~24 weeks |
Titration speed is one of the most important variables in tolerability. Climbing dose steps too quickly is the most common cause of severe nausea and GI distress. The schedules above represent the standard clinical trial protocols, but many users and prescribers adopt a slower pace — spending 4-6 weeks at each step instead of 4, or splitting dose increases into smaller increments. There is no pharmacological advantage to reaching the maximum dose quickly; the compound works at every dose level, with efficacy scaling with dose.
Not all users need or tolerate the maximum dose. Many people achieve their target weight loss at intermediate doses (e.g., 1.0-1.7 mg semaglutide or 7.5-10 mg tirzepatide) and remain there without further escalation. Using the lowest effective dose reduces side effect burden and cost. The semaglutide calculator and tirzepatide calculator can help with reconstitution math for each dose tier.
Side Effect Profiles
Gastrointestinal effects are the dominant tolerability concern across all three compounds. This is pharmacologically expected — GLP-1 receptor activation in the gut slows gastric emptying and alters motility, and GLP-1 receptor activation in the brainstem area postrema (the nausea center) directly triggers nausea in some individuals. These effects are most pronounced during dose titration and tend to diminish over weeks as the body adapts.
| Side Effect | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Nausea | ~44% | ~31% | ~37% |
| Diarrhea | ~30% | ~23% | ~22% |
| Vomiting | ~24% | ~12% | ~14% |
| Constipation | ~24% | ~17% | ~16% |
| Decreased appetite | ~20% | ~22% | ~25% |
| Injection site reactions | ~3.2% | ~3.2% | ~5.0% |
Several patterns emerge from the data. Tirzepatide appears to produce lower rates of nausea and vomiting than semaglutide at doses that produce greater weight loss. This is one of tirzepatide's most clinically significant advantages — better tolerability at higher efficacy. The hypothesis is that GIP receptor activation may modulate GI motility in a way that partially counteracts GLP-1's nausea-inducing effects, though the exact mechanism is still being studied.
Retatrutide's GI side effect profile appears intermediate — higher than tirzepatide on some measures, lower on others. The glucagon receptor activation introduces some unique considerations: increased heart rate (mean ~2-4 bpm elevation in trials) and potential effects on hepatic function that require monitoring. Phase 3 data will provide more clarity on the full safety profile.
A consistent finding across all GLP-1 agonist trials is that a proportion of the weight lost is lean mass (muscle), not just fat. In the STEP 1 trial, approximately 39% of the total weight lost with semaglutide was lean mass. This is a pharmacologically driven caloric deficit — the body loses both fat and muscle when in a sustained deficit without targeted countermeasures. Adequate protein intake (commonly cited as 1.6-2.2g per kg of body weight) and resistance training are the most widely discussed strategies for preserving lean mass during GLP-1-assisted weight loss. See the GLP-1 and muscle loss guide for a deeper analysis.
Half-Life and Pharmacokinetics
All three compounds are engineered for weekly dosing, but their half-lives and time to steady state differ. These differences have practical implications for missed doses, washout periods, and how quickly the compound reaches full effect after initiation.
| Compound | Half-Life | Steady State | Dosing | Missed Dose Impact |
|---|---|---|---|---|
| Semaglutide | ~7 days (168 hours) | ~4-5 weeks | Weekly SubQ | Moderate — long half-life provides buffer. Levels drop slowly. |
| Tirzepatide | ~5 days (120 hours) | ~3-4 weeks | Weekly SubQ | Slightly higher — shorter half-life means faster decline between doses. |
| Retatrutide | ~5 days (120 hours) | ~3-4 weeks | Weekly SubQ | Similar to tirzepatide. Weekly dosing maintains levels within therapeutic range. |
Semaglutide's longer half-life (~7 days) gives it a modest pharmacokinetic advantage for dose consistency. If a dose is delayed by a day or two, semaglutide levels drop less than tirzepatide or retatrutide would in the same window. This makes semaglutide somewhat more forgiving of imperfect adherence. However, at steady state, all three maintain therapeutic levels with once-weekly dosing — the 5-day half-life of tirzepatide and retatrutide is adequate for a 7-day dosing interval.
Steady state — the point where weekly administration rate equals weekly elimination rate and blood levels stabilize — is reached in approximately 4-5 half-lives. For semaglutide, this means about 4-5 weeks at any given dose. For tirzepatide and retatrutide, approximately 3-4 weeks. This is why titration steps are typically 4 weeks apart: it allows the compound to reach steady state before assessing whether a dose increase is needed. Understanding where levels sit within the dosing cycle is part of what saturation and steady state tracking is designed to show.
Availability and Status
Semaglutide — Widely Available
Semaglutide is FDA-approved under two brand names: Ozempic (for type 2 diabetes, doses up to 2.0 mg) and Wegovy (for chronic weight management, doses up to 2.4 mg). It is the most established GLP-1 agonist for weight loss, with the largest body of published clinical evidence. Supply constraints that affected availability in 2023-2024 have largely resolved. Generic semaglutide is not yet available, but compounding pharmacies have offered compounded versions during shortage periods — a regulatory landscape that continues to evolve.
Tirzepatide — Approved, Supply Improving
Tirzepatide is FDA-approved as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). Manufactured by Eli Lilly, it has experienced intermittent supply constraints since launch. Availability has been improving through 2025-2026 as manufacturing capacity scales. Tirzepatide is increasingly positioned as the preferred option for users who have plateaued on semaglutide or who want the dual-agonist approach. Compounded tirzepatide availability follows a similar regulatory trajectory to semaglutide.
Retatrutide — Not Yet Approved
Retatrutide is in Phase 3 clinical trials conducted by Eli Lilly. Phase 2 results were published in 2023 and generated significant attention due to the ~24% average weight loss at the highest dose — the largest ever reported for a pharmacological weight loss agent. Phase 3 results are expected to report in 2025-2026, with potential FDA approval following successful review. Optimistic timelines suggest commercial availability around 2026-2027. In the interim, retatrutide is available through compounding pharmacies and research peptide vendors, though these products operate outside the FDA approval framework.
Compounded versions of semaglutide, tirzepatide, and retatrutide are sourced differently from brand-name medications. Quality, purity, and potency can vary between vendors. The regulatory status of compounded GLP-1 agonists has been evolving — FDA enforcement actions, state pharmacy board decisions, and manufacturer patent positions all affect availability. Users sourcing from compounding pharmacies commonly track their protocol closely because dosing precision matters more when product consistency is less guaranteed.
Head-to-Head Summary
The following table consolidates the key comparison points across all three compounds.
| Metric | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor targets | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Avg weight loss | ~15% | ~22% | ~24% |
| Half-life | ~7 days | ~5 days | ~5 days |
| Max dose | 2.4 mg/week | 15 mg/week | 12 mg/week |
| Nausea incidence | ~44% | ~31% | ~37% |
| FDA status | Approved | Approved | Phase 3 trials |
| Availability | Widely available | Available, supply improving | Compounding/research only |
| Clinical data depth | Extensive (STEP 1-8) | Strong (SURMOUNT 1-4) | Limited (Phase 2 only) |
| Injection frequency | Weekly | Weekly | Weekly |
| Route | SubQ | SubQ | SubQ |
The data pattern across all three is consistent: more receptor targets correlates with greater weight loss efficacy. Semaglutide, as a single GLP-1 agonist, has the longest track record and most extensive safety data. Tirzepatide's dual mechanism produces meaningfully greater weight loss with a comparable or better side effect profile — making it increasingly the compound of choice for new starts. Retatrutide's triple mechanism shows the highest efficacy numbers in early data, but the absence of Phase 3 results and FDA approval means it carries more uncertainty.
For users already on one compound considering a switch, the decision typically involves weighing current efficacy (has weight loss plateaued?), tolerability (are side effects manageable?), availability (can you consistently source it?), and cost. Switching between these compounds is common in clinical practice and generally involves restarting the titration schedule of the new compound from a low dose.
Regardless of which compound is used, consistent tracking of dose, weight, subjective markers (appetite, energy, GI symptoms), and adherence provides the data needed to optimize the protocol over time. Understanding where levels sit relative to steady state and how each dose change affects the pharmacokinetic curve is what separates an optimized protocol from guesswork.
Frequently Asked Questions
Which GLP-1 agonist is most effective for weight loss?
Based on published clinical trial data, retatrutide has demonstrated the highest average weight loss at approximately 24% body weight reduction at the 12 mg dose over 48 weeks in Phase 2 trials. Tirzepatide follows at approximately 22.5% at the 15 mg dose over 72 weeks (SURMOUNT-1). Semaglutide produced approximately 15% at the 2.4 mg dose over 68 weeks (STEP 1). However, retatrutide's data comes from Phase 2 only — smaller sample sizes and potentially more optimistic than Phase 3 will show. Among currently approved compounds, tirzepatide has the strongest weight loss data. Individual responses vary significantly within all trials.
Can you switch between semaglutide and tirzepatide?
Switching between GLP-1 agonists is commonly done in clinical practice. The most frequent switch is from semaglutide to tirzepatide — typically when weight loss has plateaued on semaglutide or the user wants to try the dual-agonist mechanism. Standard practice is to restart the titration of the new compound from the lowest dose to assess tolerance, rather than attempting to match the previous dose. Starting the new compound on the week the old one would have been due provides a natural transition. Some users experience a temporary return of GI side effects during the switch as the body adjusts to the new compound's receptor profile.
Do GLP-1 agonists work without diet and exercise?
The clinical trials for all three compounds demonstrated significant weight loss with standard lifestyle counseling only — no mandated diet or exercise program. The weight loss is primarily driven by reduced appetite and caloric intake via central GLP-1 receptor activation in appetite-regulating brain regions. However, the composition of weight lost matters: without adequate protein intake and resistance training, a meaningful portion of weight lost is lean mass (muscle), not just fat. The compounds create the caloric deficit through appetite suppression; dietary choices and training determine whether the weight lost is predominantly fat or a mix of fat and muscle.
When will retatrutide be available?
Retatrutide is currently in Phase 3 clinical trials run by Eli Lilly. Phase 2 results published in 2023 were highly promising. Phase 3 trial results are expected in 2025-2026, with potential FDA approval and commercial launch optimistically estimated around 2026-2027 if trials are successful. Until then, retatrutide is available only through compounding pharmacies and research peptide vendors — sources that operate outside the FDA approval framework with variable quality assurance. The retatrutide compound page has additional detail on the current state of the clinical program.
Which GLP-1 agonist has the fewest side effects?
Among the three compounds, tirzepatide has demonstrated the lowest incidence of nausea and vomiting in clinical trials — approximately 31% nausea vs 44% for semaglutide — while producing greater weight loss. This is thought to result from the GIP receptor component modulating gastrointestinal motility differently than GLP-1 alone. However, side effect profiles are highly individual and dose-dependent. Most GI side effects are worst during titration phases and diminish as the body adapts over 2-4 weeks at each dose level. Slow, patient titration is the most effective strategy for minimizing side effects across all three compounds.